Robust evidence was assigned to PCSK9 inhibition (OR = 0.85, 95% CI: 0.76, 0.96) and hyperthyroidism (increased susceptibility, OR = 0.86, 95% CI: 0.79, 0.94) with relatively small sample size. This evidence concerns the gene PCSK9 and hyperthyroidism.